Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 500259 | NSE Symbol : LYKALABS | ISIN : INE933A01014 | Industry : Pharmaceuticals |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
22-Oct-2024	12-Nov-2024	Quarterly Results	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve As per attachment. (As Per BSE Announcement Dated on 12.11.2024)
04-Oct-2024	11-Oct-2024	Scheme of Amalgamation	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/10/2024 inter alia to consider and approve As per attachment As per attachment (As Per BSE Announcement Dated on 11.10.2024)
01-Aug-2024	09-Aug-2024	Quarterly Results	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve The Company submit the details of Board Meeting to be held on 9th August 2024 as detailed therein. Outcome of Board Meeting held on 9th August 2024 The Company has accept the Resignation of Mr. Kishore P. Shah Company Secretary and Compliance Officer of the Company. (As Per BSE Announcement dated on 09.08.2024)
10-May-2024	21-May-2024	Accounts	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 inter alia to consider and approve The Company has informed that the meeting of Board of Directors of the Company is scheduled on 21st May 2024 to consider and approve standalone and consolidated financial results for the year ended 31st March 2024. The Board Meeting to be held on 21/05/2024 has been revised to 21/05/2024 Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation to our prior intimations dated 10th May 2024, relating to the Board Meeting scheduled on Tuesday, 21st May 2024, this is to inform you that the said meeting is rescheduled at 03:30 p.m. instead of 12:00 noon, inter alia to consider and approve Audited Standalone and Consolidated Financial Results for the quarter and financial year ended on 31st March 2024. (As Per BSE Announcement Dated on 14.05.2024) Outcome of Board Meeting (As Per BSE Announcement Dated on 21/05/2024)
08-Apr-2024	16-Apr-2024	Conversion	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/04/2024 inter alia to consider and approve to allot and issue 2600000 equity shares upon conversion of 2600000 warrants to Ipca Laboratories Limited. Outcome of Board Meeting (As Per BSE Announcement Dated on 16.04.2024)
31-Jan-2024	08-Feb-2024	Quarterly Results	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended on 31st December 2023 to be held on Thursday 8th February 2024 at 12:00 noon at 125 - Charkop Road Charkop Industrial Estate Kandivali West Mumbai - 400 067. Outcome of Board Meeting held on 8th February 2024 Financial Results for the quarter and nine months ended 31.12.2023 (As per BSE Announcement Dated on 08/02/2024)
16-Jan-2024	16-Jan-2024	EGM	Pursuant to NCLT Order dated 8.01.2024, the Board of Directors in its meeting held on 16th January 2024 has consented to convey meetings of its shareholders and creditors Board of Directors of the Company, in its meeting held on 16trh January 2024, has decided to to seek consent of members through postal ballot. (As per BSE Announcement Dated on 16/01/2024)
20-Oct-2023	02-Nov-2023	Quarterly Results	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2023 inter alia to consider and approve The meeting of the Board of Directors of the Company to be held on Thursday 2nd November 2023 at 12:00 noon at 125 - Charkop Road Charkop Industrial Estate Kandivali West Mumbai - 400 067 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended on 30th September 2023. Outcome of the Board Meeting held on 02.11.2023 (As Per BSE Announcement dated on 02.11.2023)
26-Jul-2023	02-Aug-2023	Quarterly Results	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 inter alia to consider and approve Meeting of the Board of Directors of the Company to be held on Wednesday 2nd August 2023 at 1.00 p.m. at Ground Floor Spencer Building 30 Forjett Street Grant Road (West) Mumbai - 400 036 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June 2023. In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; the Board of Directors at its Meeting held today i.e. 2nd August 2023 inter alia considered and approved Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2023 together with the Limited Review Reports thereon. The said Financial Results along with Limited Review Report are attached herewith. The meeting of the Board of Directors commenced at 01:00 p.m. and concluded at 01:50 p.m. The Board of Directors at its meeting held today i.e. 2nd August 2023 inter-alia considered and approved unaudited standalone and consolidated financial results for the quarter ended 30th June 2023. (As Per BSE Announcement Dated on 02.08.2023)
16-May-2023	23-May-2023	Accounts	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 inter alia to consider and approve This is to inform that a meeting of the Board of Directors of the Company is schedule to be held on Tuesday 23rd May 2023 at 11.30 a.m. at 125- Charkop Road Charkop Industrial Estate Kandivali West Mumbai - 400 067 inter alia to consider and approve Audited Standalone and Consolidated Financial Results for the quarter and financial year ended on 31st March 2023. The Board of Directors at its Meeting held today i.e. 23rd May 2023 inter alia transacted the following; - Considered and approved Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31st March 2023 together with the Auditors' Report., also enclosed we enclose the following Audited Standalone and Consolidated Financial Results for the quarter and the financial year ended on 3st March 2023, Statement of Assets and Liabilities along with Auditors'' Report on Audited Financial Results (Standalone and Consolidated) as at 31st March 2023 and the Statement of Cash flows for the half-year ended 31st March 2023 and the Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, stating that the Report of Auditors with respect to the Audited Financial Results (Standalone and Consolidated) for the quarter and the financial Year ended 31st March 2023, is issued with unmodified opinion. (As Per BSE Announcement Dated on 23/05/2023)
11-Apr-2023	18-Apr-2023	Conversion	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/04/2023 inter alia to consider and approve A meeting of the Board of Directors of the Company is schedule to be held on Tuesday 18th April 2023 at 11:30 a.m. (IST) at 125 - Charkop Road Charkop Industrial Estate Kandivali West Mumbai - 400 067 inter alia: to allot and issue 2400000 Equity Shares upon conversion of 2400000 Warrants to Ipca Laboratories Limited part of a Promoter Group. In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; the Board of Directors at its meeting held today i.e. 18th April 2023 inter alia considered the allotment and issue of 24,00,000 Equity Shares upon conversion of 24,00,000 Warrants to Ipca Laboratories Limited, a part of 'Promoter Group'. (As Per BSE Announcement Dated on 18.04.2023)
08-Mar-2023	15-Mar-2023	Preferential Issue	Preferential Issue of shares & Issue Of Warrants Inter alia: to allot and issue 20,00,000 Equity Shares and 50,00,000 Warrants convertible into Equity Shares to Ipca Laboratories Limited and to approve draft of Postal Ballot Notice for seeking approval of shareholders for Re-appointment of Mr. Yogesh Shah as an Executive Director. In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; the Board of Directors at its Meeting held today i.e. 15th March 2023 inter alia transacted the following; 1. Allotment and issue 20,00,000 equity shares to Ipca Laboratories Limited 2. Allotment and issue 50,00,000 warrants convertible into equity shares to Ipca Laboratories Limited 3. Approval of Postal Ballot Notice for seeking approval of members for re-appointment of Mr. Yogesh Shah as an Executive Director. The meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 12.10 p.m. (As Per BSE Announcement dated on 15.03.2023)
31-Jan-2023	07-Feb-2023	Quarterly Results	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2023 inter alia to consider and approve A meeting of the Board of Directors of the Company is schedule to be held on Tuesday 7th February 2023 at 12.30 p.m. at 125- Charkop Road Charkop Industrial Estate Kandivali West Mumbai - 400 inter alia to consider and approve Un-audited Standalone and Consolidated Financial Results for the third quarter ended on 31st December 2022 In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; the Board of Directors at its Meeting held today i.e. 7th February 2023 inter alia transacted the following; 1. Un-audited Standalone and Consolidated Financial Results for the third quarter ended 31st December 2022 together with Limited Review Report. The said Financial Results along with Limited Review Report are attached herewith. 2. The Board has recommended the reappointment of Mr. Yogesh B. Shah as an Executive Director for the period 3 (three) years subject to approval of Members. The meeting of the Board of Directors commenced at 12:30 p.m. and concluded at 1.40 p.m. In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)Regulation, 2015; the Board of Directors at its Meeting held today i.e. 7th February 2023 inter alia transacted the following; 1. Un-audited Standalone and Consolidated Financial Results for the third quarter ended 31st December 2022 together with Limited Review Report. The said Financial Results along with Limited Review Report are attached herewith. 2. The Board has recommended the reappointment of Mr. Yogesh B. Shah as an Executive Director for the period 3 (three) years subject to approval of Members. The meeting of the Board of Directors commenced at 12:30 p.m. and concluded at 1.40 p.m. (As Per BSE Announcement Dated on 07.02.2023)
18-Jan-2023	21-Jan-2023	Preferential Issue	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2023 inter alia to consider and approve A meeting of the Board of Directors of the Company is schedule to be held on Saturday 21st January 2023 at the Corporate Office of the Company inter alia to consider and evaluate proposal for raising of funds by way of issue of equity shares or any other eligible convertible securities through permissible modes or combination of both subject to all such regulatory/ statutory approvals as may be required including the approval of shareholders of the Company. In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; this is to inform you that the Board of Directors at its Meeting held today i.e.21st January 2023 inter alia transacted the following; 1. Issue of Equity Shares and Warrants convertible into Equity Shares on preferential basis to Promoter Group 2. Convening of Extra Ordinary General Meeting (EOGM) of the Company (As Per BSE Announcement Dated on 21/01/2023)
01-Nov-2022	09-Nov-2022	Quarterly Results	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022 inter alia to consider and approve We wish to inform you that the meeting of Board of Directors of the Company is to be held on Wednesday 9th November 2022 at 125 Charkop Road Charkop Industrial Estate Kandivali West Mumbai - 400 067 inter alia to consider and approve Standalone and Consolidated Un-Audited Financial Results for the Second Quarter and Half year ended on 30th September 2022. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)Regulation, 2015; the Board of Directors in its meeting held today i. e.9th November 2022 considered and approved the following: 1. The Standalone and Consolidated Unaudited Financial Results for the quarter and the half year ended 30th September 2022 2. Noting resignation of Mr. Piyush G. Hindia, Company Secretary and Compliance officer of the Company. 3. Appointment of Mr. Kishore P. Shah, as Company Secretary and Compliance Officer of the Company 4. Appointment of Mr. Kishore P. Shah, as Nodal Officer under Investor Education and Protection Fund (IEPF) Rules, 2016. 5. The Board has considered acquisition of animal healthcare business from Agilis Healthcare Private Limited The Standalone and Consolidated Unaudited Financial Results for the quarter and the half year ended 30th September 2022 (As Per BSE Announcement Dated on 09/11/2022)

1 2

LOGIN HERE

Lyka Labs Ltd

Board Meeting